Skip to main content
CORESTEMCHEMON Inc. logo

CORESTEMCHEMON Inc. — Investor Relations & Filings

Ticker · 166480 ISIN · KR7166480004 KO Professional, scientific and technical activities
Open in API
Filings indexed 274 across all filing types
Latest filing 2019-03-13 Regulatory Filings
Country KR South Korea
Listing KO 166480

About CORESTEMCHEMON Inc.

https://www.corestemchemon.com/eng/main…

CORESTEMCHEMON Inc. is a biotechnology company operating through two main divisions: a biopharmaceutical unit and a non-clinical Contract Research Organization (CRO) unit. The biopharmaceutical division is dedicated to the research and development of new drugs based on stem cell therapy technology. Its clinical pipeline primarily targets neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and multiple sclerosis, as well as autoimmune diseases like systemic lupus erythematosus (SLE) and fibrosis. The non-clinical CRO division provides comprehensive preclinical services, conducting essential toxicity and efficacy evaluations for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices to support regulatory approval processes.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
Regulatory Filings Classification · 1% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (Corestem) scheduled its AGM on a date that coincides with the KOSDAQ Association's 'concentrated' dates. Since this is a specific regulatory disclosure regarding meeting logistics and compliance with KOSDAQ guidelines, and does not fit into the specific categories for AGM materials, proxy statements, or voting results, it is classified as a general regulatory filing.
2019-03-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Corestem. It outlines the date, location, and specific agenda items (such as financial statement approval, director appointments, and remuneration limits) to be voted on at the upcoming meeting. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of the meeting agenda and request their participation/votes.
2019-03-05 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 1% confidence The document is a regulatory filing from a Korean company (Corestem) announcing a significant change (over 15-30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (KRX) for preliminary earnings results. Since it provides specific financial highlights and performance metrics rather than just announcing the availability of a report, it is classified as an Earnings Release (ER).
2019-03-05 Korean
분기보고서 (2018.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for Corestem Inc. covering the period from January 1, 2018, to September 30, 2018. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-11-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.